Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02747108 · ClinicalTrials.gov registry record · NA
ForgIng New Paths to Prevent DIabeTes (FINDIT)
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 315
- Enrollment target
NCT02747108: Completed NA study, sponsored by VA Office of Research and Development.
NCT02747108 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 315 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02747108, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 315 participants
- Enrollment target
Study Summary
This study will evaluate the effects of screening for type 2 diabetes mellitus (T2DM) and brief counseling about screening test results on weight and key health behaviors among Veterans with risk factors for T2DM. Study participants will be randomly assigned to one of two study groups: (1) Blood Test Group or (2) Brochure Group. Participants in the Blood Test Group will complete a blood test called hemoglobin A1c (HbA1c) which measures average blood sugar levels. Participants will receive brief counseling about the results from their primary care provider or someone authorized to speak on their behalf. Participants randomly selected for the Brochure Group will review a handout from the VA National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations. All participants will be asked to complete a survey prior to study group assignment, immediately after a Primary Care appointment, 3 months after enrollment, and 12 months after enrollment.
Primary Outcome
The primary outcome will be weight change 12 months after an HbA1c test and brief counseling or review of health promotion literature.
Interventions
- BEHAVIORAL Blood Test Group Intervention
- BEHAVIORAL Brochure Group Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2015-12-02 |
| Est. Completion | 2020-03-30 |
| Phase | NA |
What the finished NCT02747108 record still lists
NCT02747108 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Blood Test Group Intervention is the first listed.
NCT02747108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02747108 about?
NCT02747108 is a clinical study titled "ForgIng New Paths to Prevent DIabeTes (FINDIT)". This study will evaluate the effects of screening for type 2 diabetes mellitus (T2DM) and brief counseling about screening test results on weight and key health behaviors among Veterans with risk factors for T2DM. Study participants will be randomly assigned to one of two study groups: (1) Blood Tes...
What is the current status of trial NCT02747108?
This trial is currently completed. It is a NA study. The enrollment target is 315 participants. The study started on 2015-12-02. Estimated completion is 2020-03-30.
What interventions are being tested in trial NCT02747108?
The interventions under investigation include: Blood Test Group Intervention (BEHAVIORAL), Brochure Group Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT02747108?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02747108's enrollment target sits among peer trials
315 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI